Clinical Trial Update: Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating nivolumab combined with eribulin in HER2-negative metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• nivolumab (nivolumab)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: UNKNOWN